Fig. 1a

Fig. 1b

Fig. 1c

Fig. 1d

Fig. 1e

Fig. 1f

Fig. 1g

Fig. 2a

Fig. 2b

IL-2 [ng/ml]

Thymidine incorporation
[relative units]

Fig. 3

Fig. 4a

Fig. 4b

Fig. 4c

Atorvastatin

Lovastatin

Fig. 5a

Pravastatin Sodium

Fluvastatin

Fig. 5b

Mevastatin

Simvastatin

Fig. 5c

Fig. 6

Fig. 7

A)

MCP-1 [pg/ml]

B)

IL-6 [pg/ml]

C)

IL-8 [ng/ml]

1 Control
2 rCD40L (5µg/ml)
3 rCD40L + pravastatin (5µM)
4 rCD40L + lovastatin (5µM)
5 rCD40L + atorvastatin (5µM)
6 rCD40L + simvastatin (5µM)
7 rCD40L + simvastatin (5µM) + L-Mevalonate (200µM)

* p<0.02   ** p<0.05

Fig. 8

Fig. 9a

Statin treatment

− +

CD40L staining

Fig. 9b

Fig. 9c

Day 10 after Tx

## Day 14 after Tx

Fig. 10

Day 6 after onset of arthritis

Day 12 after onset of arthritis

Control   Low dose   High dose

Statin

Fig. 11

	[³H] Thymidine incorporation [cpm]	IFN-γ production [pg/ml]
Control	13,830 (± 7,078)	60,112 (± 13,532)
Low dose	6,508 (± 6,499) *	36,368 (± 8,005) *
High dose	5,221 (± 7,632) *	29,805 (± 8,114) *

Fig. 12